FIELD: pharmacology.
SUBSTANCE: invention group is a nanoparticle for retroviral infection suppression, comprising at least one therapeutic agent and at least one surfactant, wherein the said nanoparticle is crystalline, wherein the said surfactant covers a crystal of the said therapeutic agent, wherein the said therapeutic agent is selected from the group consisting of atazanavir (ATV), efavirenz (EFV), indinavir (IDV) and ritonavir (RTV), wherein the said surfactant is an amphiphilic block copolymer, wherein the said nanoparticle is obtained by wet grinding or high pressure homogenization, and wherein the said nanoparticle contains at least 95% of a therapeutic agent; composition for retroviral infection suppression; method for HIV infection treatment or suppression.
EFFECT: invention provides steady drug delivery to the serum and tissue and improved antiviral efficacy relative to the equivalent dose of the free drug.
18 cl, 5 ex, 4 tbl, 25 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CCR5 EXPRESSION SUPRESSION COMPOSITIONS AND METHODS OF APPLICATION THEREOF | 2004 |
|
RU2353357C2 |
| COMPOSITIONS AND METHODS FOR DRUG DELIVERY | 2009 |
|
RU2496482C2 |
| METHOD FOR OBTAINING VACCINE FOR TREATING TUBERCULOSIS AND OTHER INTRACELLULAR INFECTIOUS DISEASES AND VACCINE OBTAINED ACCORDING TO DECLARED METHOD | 2001 |
|
RU2262950C2 |
| TREATMENT OF HIV INFECTION AT MEDICINAL RESISTANCE | 2000 |
|
RU2265439C2 |
| PEG-YLATED NANOPARTICLES | 2005 |
|
RU2400215C2 |
| RNA-guided destruction of human JC virus and other poliomaviruses | 2015 |
|
RU2747722C2 |
| METHODS OF TREATING HIV-1 INFECTION | 2020 |
|
RU2827716C1 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| PRODUCTS FOR DELIVERING THERAPEUTIC/DIAGNOSTIC COMPOUNDS TO THE HEART | 2015 |
|
RU2721778C2 |
| FACTOR EFFECTING ON ACTIVITY OF TUMOR NECROSIS FACTOR RECEPTOR-RELEASING ENZYME | 1999 |
|
RU2279478C2 |
